Treatment for Lupus
- Benlysta (belimumab) to treat systemic lupus, an autoimmune disease that attacks healthy tissues, Human Genome Sciences, Inc. and GlaxoSmithKline
Benlysta is the first in a new class of drugs to treat systemic lupus, and the first new treatment for lupus in over 50 years.
Heart Attack and Stroke Drugs
- Brilinta (ticagrelor) to reduce cardiovascular death and heart attack, AstraZeneca
Brilinta was deemed to outperform Pradaxa, the first oral anticoagulant approved since warfarin in the 1950s for the prevention of stroke and blood clots in patients with abnormal heart rhythm (atrial fibrillation).
New Antibiotic for MRSA Infections
- Teflaro (ceftaroline fosamil), an injectable antibiotic for treating bacterial skin infections and pneumonia, Forest Laboratories, Inc.
Because of MRSA's multi-drug resistance, the FDA facilitated the development of this new antibiotic through a Fast Track review process.
Prevention of Kidney Transplant Rejection
- Nulojix (belatacept) to prevent rejection of transplanted kidneys, Bristol-Myers Squibb
Nulojix is the first drug in a new class of primary immunosuppressants to prevent acute organ rejection in adult kidney transplant patients and is the first new drugs for preventing organ rejection in more than a decade.
